Rahul Gosain: Osimertinib now FDA approved after LAURA Phase III study

Rahul Gosain shared the following on LinkedIn:

“Osimertinib now FDA approved based off LAURA: Ph III, Indefinite Osimertinib after ChemoXRT in Stage III mEGFR NSCLC: New SoC.

Key results:

• Increase PFS with Osi, 39.1mos vs 5.6mos (HR 0.16)
• 2yr PFS: 65% vs 13%
• Improved CNS PFS
• ≥Gr 3 AEs: 35% vs 12%.”

Source: Rahul Gosain/LinkedIn

Drs. Rohit Gosain and Rahul Gosain (aka Oncology Brothers),  are medical oncologists/hematologists. Through their social media platforms like X/Twitter, they actively engage with their audience. With their own YouTube channel and podcast, they provide accessible resources for cancer patients and their families.

Additionally, their participation in live conferences ensures that cancer patients receive the best care closer to home, reflecting their commitment to advancing oncology and improving patient outcomes through education and outreach.